文献速递胸部肿瘤放疗放疗物理与技术

胸椎椎体剂量学在减少接受肺部放疗和免疫治疗的非小细胞肺癌患者急性血液学毒性中的作用

The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Patients With Non-Small Cell Lung Cancer Receiving Lung Radiation Therapy and Immunotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-30

本研究纳入132例接受肺部放疗联合PD-(L)1免疫治疗的非小细胞肺癌患者,分析胸椎椎体(T1-T10)剂量学参数与≥3级血液学毒性(HT3+)的关系。多因素分析显示DmeanEQD2及V5EQD2-V20EQD2与HT3+相关,ROC分析确定各参数阈值,超过阈值者HT3+风险增加一倍以上,且放疗后绝对淋巴细胞计数和免疫治疗反应有显著差异。作者认为应用胸椎椎体剂量约束可能减少HT3+并避免免疫反应减弱,但需前瞻性验证。

要点

  • 132例中26例(19.7%)发生≥3级血液学毒性。
  • DmeanEQD2及V5EQD2-V20EQD2与HT3+独立相关(P均<.05)。
  • 超过ROC阈值者HT3+风险增加一倍以上,淋巴细胞计数和免疫反应显著更差。

核心结论

  • 作者认为胸椎椎体剂量学可能与接受肺部放疗联合免疫治疗的非小细胞肺癌患者的HT3+相关,应用胸椎椎体剂量约束可能减少HT3+并避免免疫反应减弱,但需前瞻性验证。

研究设计与样本

  • 回顾性分析132例接受肺部放疗联合程序性细胞死亡(配体)1免疫治疗的非小细胞肺癌患者,所有剂量统一报告为2 Gy等效剂量(EQD2),胸椎椎体体积指T1-T10,采用逻辑回归分析剂量学/临床参数与HT3+的关联,构建正常组织并发症概率(NTCP)模型,ROC分析确定剂量学阈值,AUC通过自举法(乐观校正)验证。

主要发现

  • 132例患者中26例(19.7%)发生HT3+。
  • 多因素分析显示DmeanEQD2及V5EQD2至V20EQD2与HT3+相关(P均<.05)。
  • NTCP模型显示HT3+概率为50%时对应的参数值为DmeanEQD2=39.8 Gy、V5EQD2=87.4%、V10EQD2=77.0%、V20EQD2=68.4%。
  • ROC分析确定的HT3+最佳阈值分别为DmeanEQD2±30.2 Gy、V5EQD2±69.1%、V10EQD2±64.6%、V20EQD2±53.5%。
  • 超过上述阈值的患者HT3+风险增加一倍以上,且放疗后绝对淋巴细胞计数和免疫治疗反应有显著差异(P均<.05)。

关键数值与推荐

  • NTCP模型:HT3+概率50%对应DmeanEQD2=39.8 Gy、V5EQD2=87.4%、V10EQD2=77.0%、V20EQD2=68.4%。
  • ROC最佳阈值:DmeanEQD2±30.2 Gy、V5EQD2±69.1%、V10EQD2±64.6%、V20EQD2±53.5%。
  • 超过阈值者HT3+风险增加一倍以上,放疗后绝对淋巴细胞计数和免疫治疗反应显著更差(P均<.05)。
  • 各参数AUC为0.743至0.798,4个阈值合并AUC为0.836。

临床怎么用

  • 作者认为在此人群中应用胸椎椎体剂量约束可能减少HT3+并避免免疫反应减弱,但需前瞻性验证。

局限性

  • 原文结论指出本工作为假设生成性研究,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hematologic toxicities (HTs) are among the most common toxicities of combined immunotherapy and radiation therapy (RT). It remains essential to prevent RT-induced HTs because they can cause treatment discontinuation (influencing antitumoral effects) and because lymphopenia might dampen the effects of immunotherapy. To date, there are no studies examining the effect of thoracic vertebral body (TVB) RT dose on HTs in patients with non-small cell lung cancer receiving combined lung RT and programmed cell death (ligand) 1 immunotherapy. METHODS AND MATERIALS: For standardization, all doses were reported as 2-Gy equivalents (EQD2). Mirroring publications before the immunotherapy era, TVB volumes referred to T1-T10, and specific dosimetric parameters (DmeanEQD2, V5EQD2-V60EQD2) were analyzed. Logistic regression estimated associations between grade ≥3 HTs (HT3+) and dosimetric/clinical parameters. Normal tissue complication probability (NTCP) models were constructed by logistic regression analysis modeling for HT3+. Receiver operating characteristic (ROC) analysis delineated TVB dosimetric thresholds, the stratification of which was able to evaluate post-RT absolute lymphocyte count and immunotherapy responses. Areas under the curve (AUCs) for NTCP models were corroborated by bootstrapping (optimism-corrected) methodology. RESULTS: In 132 patients, there were 26 (19.7%) instances of HT3+. On multivariate analysis, DmeanEQD2 and V5EQD2 to V20EQD2 were associated with HT3+ (P < .05 for all). The NTCP models illustrated a 50% probability of HT3+ at a DmeanEQD2 = 39.8 Gy, V5EQD2 = 87.4%, V10EQD2 = 77.0%, and V20EQD2 = 68.4%. ROC analysis delineated optimal thresholds of HT3+ with DmeanEQD2 ± 30.2 Gy, V5EQD2 ± 69.1%, V10EQD2 ± 64.6%, and V20EQD2 ± 53.5%. Patients treated with values above those cutoffs had over double the risk of HT3+, with significant differences in post-RT absolute lymphocyte count and immunotherapy responses (P < .05 for all). AUCs for each individual parameter ranged from 0.743 to 0.798, and combining all 4 aforementioned cutoffs into a ROC curve resulted in a qualitatively higher AUC (0.836). CONCLUSIONS: This hypothesis-generating work suggests that TVB dosimetry may equate with HT3+ in patients with non-small cell lung cancer undergoing combined lung RT/immunotherapy. Applying TVB dose constraints in this population could reduce HT3+ and avoid dampening of immunotherapy responses, but prospective validation is required.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ma J, Li Y, Yu H, et al. The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Patients With Non-Small Cell Lung Cancer Receiving Lung Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 38040058. doi:10.1016/j.ijrobp.2023.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。